Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brexpiprazole + antidepressant
- Development stage
- Unknown
- Lead developer
- Otsuka Holdings
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Brexpiprazole (OPC-34712) is an atypical antipsychotic developed as a serotonin-dopamine activity modulator. It acts as a partial agonist at serotonin 1A and dopamine D2 receptors, and as an antagonist at serotonin 2A receptors. In clinical trials, "brexpiprazole + ADT" refers to the use of brexpiprazole in combination with an antidepressant treatment (ADT), such as desvenlafaxine, escitalopram, fluoxetine, paroxetine, sertraline, or venlafaxine. This combination has been studied primarily for adjunctive treatment in adults with major depressive disorder who have had inadequate response to standard antidepressants[1][3][5].
- Brand names
- Rexulti
- Other names
- brexpiprazole + ADT
02
Targets
DRD2 (Dopamine D2 Receptor)ADRA2C (α2C)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))ADRA1B (α1B)HTR2A (Serotonin receptor 5-HT2A)
Beyond the preview
Go deeper on brexpiprazole + antidepressant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brexpiprazole + antidepressant.